Calico's Levinson leaves Roche board to focus on AbbVie R&D deal

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Calico's Levinson leaves Roche board to focus on AbbVie R&D deal

Calico CEO Arthur Levinson resigned from Roche's ($RHHBY) board of directors on Thursday, effective immediately. Levinson, who served on Roche's board since 2010, decided to step down to avoid a conflict of interest, as Google subsidiary Calico recently announced a major R&D deal with Roche rival AbbVie ($ABBV). Roche has not yet named Levinson's replacement. Story

Calico/Roche
Art Levinson left his board position at Roche to focus on Calico.


Voyager
Steven Paul joined as CEO.

Biotech

> Third Rock Ventures' Voyager Therapeutics has named Dr. Steven Paul as its full-time CEO, tasking the longtime Eli Lilly ($LLY) R&D exec with shepherding its gene therapy candidates into clinical trials. Item

> Chimerix ($CMRX) has appointed Dr. W. Garrett Nichols as its chief medical officer, Essy Mozaffari as vice president of market access and reimbursement, and Odin Naderer as vice president of clinical pharmacology and translational medicine. Release

> EMD Group appointed Drew Young to be its senior vice president of neurology and immunology. Release

> Sierk Pötting joined BioNTech Group as the company's new CFO. Release

> Mast Therapeutics announced that chief medical officer Santosh Vetticaden would be leaving the company and that Edwin Parsley will take on Vetticaden's responsibilities as the interim chief medical officer. Release

> TiGenix appointed Dr. Marie Paule Richard as the company's chief medical officer and Dr. Mary Carmen Diez as its vice president of medical affairs and new product commercialization. Release

> Louis Culot joined BioData as the company's CEO. Release

> Aldeyra Therapeutics ($ALDX) expanded its drug development team with Donna Keith, Dr. Philip Piscitelli and Rachel Sorensen. Release

> Stephen Hussey and John Launie joined Emergent Health ($EMGE) as CEO and CFO, respectively. Release

Pharma

> Catalyst Pharmaceutical Partners ($CPRX) has appointed David Muth as executive vice president of corporate development. Release

> Tokai Pharmaceuticals appointed Lee Kalowski as chief financial officer. Release

Vaccines

PaxVax appointed Mark Meltz as executive vice president and chief legal officer. Release

 

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.